Somewhat Positive News Coverage Somewhat Unlikely to Affect TESARO (TSRO) Share Price
News coverage about TESARO (NASDAQ:TSRO) has been trending somewhat positive recently, Accern reports. Accern scores the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. TESARO earned a news impact score of 0.13 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 46.1154214647913 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the media headlines that may have effected Accern Sentiment’s analysis:
- The Zacks Analyst Blog Highlights: Flexion Therapeutics, Alexion Pharmaceuticals, PTC Therapeutics, Johnson & Johnson and TESARO (finance.yahoo.com)
- Are Options Traders Betting on a Big Move in Tesaro (TSRO) Stock? (finance.yahoo.com)
- Tesaro, Inc. (TSRO) noted a price change of -1.91% and Adamas Pharmaceuticals, Inc. (ADMS) closes with a move of … – Stocks Gallery (stocksgallery.com)
- Buy sentiment on Healthcare Stock: Tesaro, Inc. (TSRO) – Street Observer (press release) (streetobserver.com)
- First Week of TSRO November 17th Options Trading (nasdaq.com)
Several brokerages have recently issued reports on TSRO. Cowen and Company set a $145.00 price objective on TESARO and gave the stock a “hold” rating in a report on Saturday, June 10th. Janney Montgomery Scott set a $139.00 price objective on TESARO and gave the stock a “hold” rating in a report on Saturday, June 10th. Credit Suisse Group set a $190.00 price objective on TESARO and gave the stock a “buy” rating in a report on Friday, August 18th. Bank of America Corporation reaffirmed a “buy” rating and set a $154.00 price objective on shares of TESARO in a report on Tuesday, June 20th. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $183.00 price objective on shares of TESARO in a report on Thursday, August 10th. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $170.74.
TESARO (TSRO) opened at 119.83 on Friday. The company’s market cap is $6.49 billion. The stock’s 50 day moving average price is $122.21 and its 200 day moving average price is $135.31. TESARO has a 52-week low of $106.64 and a 52-week high of $192.94.
TESARO (NASDAQ:TSRO) last announced its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) EPS for the quarter, missing the Zacks’ consensus estimate of ($2.52) by ($0.30). TESARO had a negative return on equity of 104.00% and a negative net margin of 1,301.19%. The company had revenue of $29.50 million for the quarter, compared to analysts’ expectations of $18.61 million. During the same quarter in the previous year, the business posted ($1.28) EPS. The business’s quarterly revenue was down 17.6% compared to the same quarter last year. Analysts expect that TESARO will post ($8.63) earnings per share for the current year.
In related news, VP Grant C. Bogle sold 14,167 shares of TESARO stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $135.00, for a total transaction of $1,912,545.00. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director James O. Armitage sold 10,000 shares of TESARO stock in a transaction that occurred on Monday, September 18th. The stock was sold at an average price of $117.13, for a total value of $1,171,300.00. Following the transaction, the director now owns 10,000 shares in the company, valued at approximately $1,171,300. The disclosure for this sale can be found here. In the last quarter, insiders have sold 35,692 shares of company stock worth $4,628,976. 40.50% of the stock is currently owned by company insiders.
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.